Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences (NASDAQ: ANIX) executed a data transfer agreement (DTA) with Cleveland Clinic on Nov. 5, 2025 to move Phase 1 breast cancer vaccine clinical data and support transfer of the IND sponsorship to Anixa.
The company says Phase 1 enrollment is complete and showed encouraging immune response signals; Anixa plans to assume full IND sponsorship and advance the vaccine into a Phase 2 trial. Final Phase 1 data will be presented at the San Antonio Breast Cancer Symposium on Dec. 11, 2025.
Anixa Biosciences (NASDAQ: ANIX) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 at the Marriott Marquis Hotel in New York City. Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings.
The conference features over 60 selected companies across multiple sectors and expects more than 500 institutional and high-net-worth investors. The event includes main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions. A video recording of Anixa's presentation will be available after the conference on the company website.
Anixa Biosciences (NASDAQ: ANIX) announced that the Chinese National Intellectual Property Administration issued Patent No. ZL2020800215666, covering key aspects of its breast cancer vaccine technology and extending IP protection in China into the 2040s.
The vaccine, invented at Cleveland Clinic and exclusively licensed to Anixa, targets human α-lactalbumin to prevent and treat certain breast cancers. Anixa said this patent strengthens its global patent estate and supports future international development and commercialization. A Phase 1 trial has been completed and full results will be presented on Dec 11, 2025 at the San Antonio Breast Cancer Symposium.
Anixa Biosciences (NASDAQ: ANIX) announced completion of the final patient visit in its Phase 1 breast cancer vaccine trial on Oct 7, 2025. The study enrolled 35 women across three cohorts: 26 in triple-negative breast cancer (TNBC), 4 in a prevention cohort, and 5 given pembrolizumab concurrently. The trial is fully funded by a U.S. Department of Defense grant and the vaccine was invented in partnership with Cleveland Clinic.
Preliminary findings reported >70% of participants showed protocol-defined immune responses. Sample collection is complete; a final study report will be submitted to the Department of Defense, a Clinical Study Report will be filed with the FDA, and Cleveland Clinic will present full results at the San Antonio Breast Cancer Symposium on Dec 11, 2025.
Anixa Biosciences (NASDAQ: ANIX) announced that Cleveland Clinic will present final results from the Phase 1 clinical trial of its breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025. The trial evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer, funded by the U.S. Department of Defense.
The presentation, led by Dr. Justin Johnson, Program Manager at Cleveland Clinic and co-inventor of the vaccine technology, will provide the most comprehensive data release to date. The findings will be submitted to both the Department of Defense and FDA to guide Phase 2 planning discussions. The vaccine technology, based on decades of preclinical work by the late Dr. Vincent Tuohy at Cleveland Clinic, shows promising potential for breast cancer prevention and treatment.
Anixa Biosciences (NASDAQ: ANIX) has completed dosing the fourth cohort in its Phase 1 clinical trial for a novel FSHR-targeted CAR-T therapy treating recurrent ovarian cancer. The fourth cohort received 3×10⁶ CAR-positive cells per kilogram, a 30-fold increase from the first cohort, with no dose-limiting toxicities observed.
Several treated patients have surpassed median survival expectations, with one patient from the first cohort remaining alive 28 months post-treatment. The fifth cohort is planned to receive approximately 1×10⁷ cells/kg following a 30-day safety review. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced a time change for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place at 10:30 AM ET on September 9, 2025, at the Lotte New York Palace Hotel.
Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings during the conference, which runs from September 8-10, 2025. Interested parties can access the presentation via webcast.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.
Company President and CFO Mike Catelani will deliver a presentation on September 8, 2025, at 4:30 PM ET. The presentation will be available via webcast, and management will be available for one-on-one meetings during the conference.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent. This marks the company's first Chinese patent and will provide protection into the 2040s.
The patent, exclusively licensed from Cleveland Clinic, covers composition of matter protection for Anixa's novel breast cancer treatment and prevention approach. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers.
This expansion is particularly significant as breast cancer has become the most commonly diagnosed cancer among women in China, with hundreds of thousands of new cases annually. The patent complements existing protection in the United States and other key global markets.
Anixa Biosciences (NASDAQ: ANIX) has announced the treatment of the second patient in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The trial, conducted in partnership with Moffitt Cancer Center, is evaluating a novel treatment targeting the follicle-stimulating hormone receptor (FSHR).
Patients in the fourth cohort are receiving 3 million CAR-positive cells per kilogram of body weight, a 30-fold increase from the initial dose. Notably, no dose-limiting toxicities (DLTs) have been observed in this cohort. The study focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy, aiming to evaluate safety, determine maximum tolerated dose, and monitor clinical activity.